osimertinib
astrazeneca
['adaura', 'osimertinib', 'aura ,(-laura)']
#asco23 plenary session
overall survival analysis from the adaura trial 5y os rate
stage ii iiia 85% vs 73%, hr:0.49
stage ib iiia 88% vs 78%, hr:0.49 adjuvant osimertinib significantly improved os vs placebo presented by 
Medical Oncologist.                                            
        
On the trail of #SCIENCE to turn cancer into a manageable chronic disease. #bcsm #crcsm